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Sirs:
Severe sepsis is a major cause of mortality and morbidity
worldwide. Septic patients often develop multiple organ
dysfunction syndrome (MODS) that is characterized by an
acute functional impairment of two or more organs so that
homeostasis cannot be maintained without intervention [1].
Patients with MODS typically present with an elevated
heart rate (HR) that accompanies a highly impaired auto-
nomic dysfunction with depressed parasympathetic control
of the heart. An elevated heart rate was found to increase
the incidence of major cardiac events in critically ill
patients [2–4]. Furthermore, an elevated heart rate in the
early phase of MODS was found to be an independent
predictor of increased 28-day mortality [5].
As the currently available speciﬁc regimes for the
treatment of MODS show only very limited therapeutic
beneﬁt compared with its high incidence and mortality,
there is an urgent need for therapeutic innovations, targeted
to improve the prognosis of MODS patients is mandatory.
Ivabradine is a pure heart rate-lowering drug that acts
speciﬁcally on the sinoatrial node by selectively inhibiting
the hyperpolarization-activated cyclic nucleotide (HCN)
channel of cardiac pacemaker cells by entering and binding
to a site in the channel pore from the intracellular side
without affecting the other cardiac ionic currents.
Two very important prospective randomized trials have
showed beneﬁts derived from ivabradine administration in
patients with stable coronary artery disease and in chronic
heart failure patients [6, 7]. We previously reported a sig-
niﬁcant heart rate reduction in patients with catecholamine-
induced tachycardia after high-risk cardiac surgery treated
with ivabradine [8]. A prospective randomized trial testing
ivabradine in MODS is currently under way [9].
The aim of this case study was to report the preliminary
results of ivabradine use in three patients who developed
sepsis related MODS after cardiac surgery.
The baseline characteristics are summarized in Table 1.
A standardized anesthesia and postoperative sedation
protocol was used for all patients. Routine monitoring
included: standard 8-lead electrocardiogram, radial artery
pressure, thermodilution pulmonary artery catheter, and
transesophageal echocardiography evaluation.
Hemodynamic and metabolic outcomes were analyzed
with a hierarchical linear model for repeated measurements
to assess trends over time. Post-hoc comparisons between
the estimated means at baseline and at the end of follow-up
were investigated through suitable contrasts, for each out-
come separately. A spatial power covariance structure was
used to account for unequally spaced time occasions during
the follow-up. All analyses were performed using SAS
Statistical Package, Release 9.2 (SAS Institute, Cary, NC,
USA). All the patients developed sinus tachycardia (HR
[90 bpm). Mean arterial pressure (MAP) was sustained
with norepinephrine support. MODS manifested at the
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during the fourth postoperative day. Ivabradine was
administered twice daily via a nasogastric tube (starting
dose 10 mg followed by a maintenance dose of 5 mg/12 h)
for 18 h.
Hemodynamics, metabolic data and norepinephrine
dosage are summarized in Fig. 1.
Heart rate (mean difference -27.6) and cardiac index
(CI) decreased after ivabradine administration, whereas
end-diastolic volume index (EDVI), stroke volume index
(SVI), MAP and mixed venous saturation (SvO2)
increased. Pulmonary capillary wedge pressure
(PCWP),and right atrial pressure did not change over time.
Serum lactate levels decreased, norepinephrine dose was
reduced whereas base excess diminished.
Apache II score decreased after 24 h (31 vs. 27). All the
patients survived and were discharged from the intensive
care unit, respectively, on day 10 (patient no. 1), on day 12
(patient no. 2) and on day 18 (patient no. 3).
An elevated HR is a well established, independent and
modiﬁable risk factor for cardiovascular events and mor-
tality in critically ill patients [2]. Speciﬁcally autonomic
dysfunction with an inadequately high HR occurs very
frequently in MODS patients and is associated with a
worse prognosis [4]. Sepsis-related tachycardia has several
adverse effects on the heart, including restricted limited
diastolic ventricular ﬁlling, increased oxygen requirements
and potentially, a tachycardia-induced cardiomyopathy.
Indeed, heart rate on presentation predicted survival in
septic shock patients [10].
Ivabradine is a selective antagonist of the HCN channel.
In vitro studies showed that endotoxin sensitized HCN
channel for sympathetic stimulation, thereby increasing the
heart rate [11]. Therefore, the negative chronotropic effect
of ivabradine might be an interesting option in MODS
patients with sinus tachycardia.
In our preliminary case study ivabradine was able to
reduce HR and the three studied patients showed a con-
comitant increase in SVI, EDVI and SvO2. The hemody-
namic improvement resulted in a consistent serum lactate
level reduction and norepinephrine dosage.
Similar results are reported in a recent randomized trial
of intravenous ivabradine in the context of acute ST-seg-
ment elevation myocardial infarction. Ivabradine produced
a rapid and reversible slowing of HR not associated with
changes in blood pressure or major side effects [12].
Although there are many drugs with negative chrono-
tropic effect, such as calcium-channel blockers and b-
blockers [13], they also possess strong negative inotropic
effect and thus might be potentially harmful in most
MODS patients. Ivabradine reduces heart rate by pro-
longing diastole, while the negative ino-tropic action of b-
blockers prolongs both systole and diastole. As a result, for
the same reduction in heart rate, ivabradine produces a
greater prolongation of diastolic time than b-blocker [14].
Accordingly in our study, although not a comparative trial,
an improvement of the diastolic function has been attested
by the increase of the EDVI.
Septic shock has many of the manifestations of a hy-
peradrenergic response such as sympathetic neural and
humoral activation, catecholamine and cortisol release into
the bloodstream. The clinical and physiologic manifesta-
tions of these responses include tachycardia. Based on this
logic, in a recent single-center randomized clinical trial
Morelli et al. [15] reported that the open-label use of the
short-acting b-blocker esmolol was able to achieve reduc-
tions in heart rate to target levels, without an increase in
adverse outcomes compared with standard treatment.
Limitations of our study include the lack of power due
to the small sample size and also the lack of a randomized
group. In light of this weakness we preferred not to give
particular emphasis to our ﬁndings in terms of p values,
although the statistical methods used borrow strength from
the repeated measures design. In our view these ﬁndings
should be conﬁrmed on a larger sample size.
Pharmacokinetic data available after oral administration
of ivabradine in healthy persons demonstrated that after a
5, 10 or 20 mg single dose, a signiﬁcant reduction in HR at
2 h postdose was observed in the highest dose group,
whereas after repeated doses, a signiﬁcant reduction in HR
was observed from 2 to 4 h postdose for all three groups
[16].
Another limitation of our study is that we were unable to
measure the ivabradine plasma concentration and therefore,
demonstrate drug absorption. However, since the incidence
Table 1 Baseline characteristics
Variable Patient no. 1 Patient no. 2 Patient no.
3
Age (years) 65 62 70
Sex Male Male Male
Ejection fraction (%) 45 50 45
Acute renal failure Yes Yes Yes
Apache II score 32 30 32
ACE inhibitor Yes Yes Yes
b-blockers Yes Yes Yes
Statins Yes Yes Yes
Aortic cross clamp time
(min)
100 97 110
CPB time (min) 128 112 135
Type of infection Gram-
positive
Gram-
positive
Gram-
negative
Site of infection Endocarditis Endocarditis Lung
CPB cardiopulmonary bypass
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123of gastrointestinal dysfunction after cardiac surgery is very
low we can reasonably exclude that the treated patients
might have not absorbed the drug [17].
In conclusion our study, albeit preliminarily, demon-
strated that ivabradine administration was well tolerated
and, produced HR reduction in MODS patients. The
results of the MODI(f)Y trial are needed to conﬁrm our
ﬁndings.
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